Home Current Issue Previous Issues Published Ahead-of-Print Collections For Authors Journal Info
Skip Navigation LinksHome > October 2005 - Volume 25 - Issue 5 > Tetrahydrobiopterin in the Treatment of Children With Autist...
You could be reading the full-text of this article now...
If you have access to this article through your institution, you can view this article in OvidSP.
Journal of Clinical Psychopharmacology:
October 2005 - Volume 25 - Issue 5 - pp 485-489
Brief Reports

Tetrahydrobiopterin in the Treatment of Children With Autistic Disorder: A Double-blind Placebo-Controlled Crossover Study

Danfors, Torsten MD; von Knorring, Anne-Liis PhD; Hartvig, Per PhD; Langstrom, Bengt PhD; Moulder, Robert PhD; Stromberg, Bo PhD; Torstenson, Richard PhD; Wester, Ulrika MD; Watanabe, Yasuyoshi PhD; Eeg-Olofsson, Orvar PhD

Collapse Box

Abstract

Abstract: Twelve children, all boys, aged 4 to 7 years, with a diagnosis of autistic disorder and low concentrations of spinal 6R-l-erythro-5,6,7,8-tetrahydrobiopterin (tetrahydrobiopterin) were selected to participate in a double-blind, randomized, placebo-controlled, crossover study. The children received a daily dose of 3 mg tetrahydrobiopterin per kilogram during 6 months alternating with placebo. Treatment-induced effects were assessed with the Childhood Autism Rating Scale every third month. The results showed small nonsignificant changes in the total scores of Childhood Autism Rating Scale after 3- and 6-month treatment. Post hoc analysis looking at the 3 core symptoms of autism, that is, social interaction, communication, and stereotyped behaviors, revealed a significant improvement of the social interaction score after 6 months of active treatment. In addition, a high positive correlation was found between response of the social interaction score and IQ. The results indicate a possible effect of tetrahydrobiopterin treatment.

© 2005 Lippincott Williams & Wilkins, Inc.

Login




Help

Forgot Password?